Markets:

Overview

News

Currencies

International

Treasuries

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

1.950 +0.040 (+2.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioXcel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 25, 2023

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 25, 2023

Via Benzinga

Where BioXcel Therapeutics Stands With Analysts ↗

September 08, 2023

Via Benzinga

BioXcel Therapeutics Inc. (NASDAQ: BTAI) Leading the Way in Wednesday Trading Based on Percentage Gain

October 25, 2023

Via Investor Brand Network

Topics Artificial Intelligence

Shell Layoffs 2023: What to Know About the Latest SHEL Job Cuts ↗

October 25, 2023

Shell layoffs are on the horizon as the petrol company prepares to cut 200 jobs in 2024 with another 130 jobs under review.

Via InvestorPlace

Topics Energy Workforce

EVGO Stock Slips as TD Cowen Downgrades EVgo ↗

October 25, 2023

EVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut.

Via InvestorPlace

Nasdaq Down 1.5%; Microsoft Posts Upbeat Results ↗

October 25, 2023

U.S. stocks traded lower this morning, with the Nasdaq Composite falling 1.5% on Wednesday. Following the market opening Wednesday, the Dow traded down 0.26% to 33,053.68 while the NASDAQ fell 1.50% to...

Via Benzinga

Topics Stocks

Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today? ↗

October 25, 2023

BioXcel Therapeutics stock is rising on Wednesday as investors in BTAI stock react to results from an audit on a clinical trial.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 25, 2023

Via Benzinga

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 11, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Schizophrenia Player BioXcel's Drug Faces Funding Headwinds, Analyst Downgrades Stock ↗

October 05, 2023

Truist downgraded BioXcel Therapeutics Inc (NASDAQ: BTAI) from Buy to Hold, citing significant near-term funding and

Via Benzinga

Why Shares of BioXcel Therapeutics Fell This Week ↗

September 28, 2023

The company's co-founder is leaving, and layoffs are coming.

Via The Motley Fool

Topics Workforce

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 ↗

October 05, 2023

Via Benzinga

NASDAQ: BTAI Investor Alert: Deadline on September 5, 2023 in Lawsuit Against BioXcel Therapeutics, Inc. ↗

September 05, 2023

San Diego, CA -- (SBWIRE) -- 09/05/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 5, 2023 in the lawsuit filed for certain investors of BioXcel Therapeutics,...

Via SBWire

Topics Lawsuit

BTAI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI

September 04, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

BTAI DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

September 03, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

BIOXCEL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioXcel Therapeutics, Inc. and Encourages Investors to Contact the Firm

September 01, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

BIOXCEL 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

September 01, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)

September 01, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

September 01, 2023

Via ACCESSWIRE

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

August 29, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

August 28, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, and Baxter and Encourages Investors to Contact the Firm

August 27, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

August 27, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI

August 26, 2023

From The Rosen Law Firm PA

Via GlobeNewswire

BioXcel Therapeutics, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BTAI Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

August 23, 2023

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

August 22, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

August 22, 2023

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm

August 21, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, A TOP RANKED FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

August 19, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

BioXcel Therapeutics, Inc. - Common Stock (NQ:BTAI)

All News about BioXcel Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today